A

    Aprea Therapeutics Inc (APRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.80
    -0.04 (-4.60%)

    Market Cap: $10.56M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    64%(18/28)
    Avg Surprise
    -5.09%
    Streak
    3 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.07
    Range$-0.09 - $-0.06
    3 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.23-213.8%
    60d ago$-0.23-213.8%
    30d ago$-0.23-213.8%
    7d ago$-0.23-213.8%
    Current$-0.07
    Revenue Consensus
    $153750
    Range$0 - $615000
    4 analysts
    Dec 31, 2026
    EPS Consensus$0.21
    Range$0.13 - $0.25
    3 analysts
    Revenue Consensus
    $128250
    Range$-280250 - $1M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.21---
    Sep 26EST
    		-$-0.07---
    Jun 26
    		$-0.07N/A+68.18%Beat+86.8%
    Mar 26
    		$-0.22$-0.23+4.35%Beat+66.5%
    Dec 25
    		$-0.32$-0.36+11.11%Beat+34.7%
    Sep 25
    		$-0.47$-0.34-38.24%Miss+26.6%
    Jun 25
    		$-0.53$-0.71+25.35%Beat+8.6%
    Mar 25
    		$-0.66$-1.00+34.39%Beat+2.1%
    Dec 24
    		$-0.49$-0.54+9.26%Beat+46.7%
    Sep 24
    		$-0.64$-0.74+13.51%Beat+25.6%
    Jun 24
    		$-0.58$-0.60+3.33%Beat+33.3%
    Mar 24
    		$-0.67$-0.80+16.25%Beat+50.0%
    Dec 23
    		$-0.92$-0.77-19.48%Miss+0.0%
    Sep 23
    		$-0.86$-1.04+17.31%Beat+64.2%
    Jun 23
    		$-0.87$-1.38+36.96%Beat+95.6%
    Mar 23
    		$-1.34$-0.82-63.41%Miss+81.4%
    Dec 22
    		$-0.92N/A+70.13%Beat+87.2%
    Sep 22
    		$-2.40$-1.60-50.00%Miss+73.3%
    Jun 22
    		$-19.63$-6.20-216.61%Miss-104.5%
    Mar 22
    		$-7.20$-7.60+5.26%Beat+21.7%
    Dec 21
    		$-7.20$-8.80+18.18%Beat+50.7%
    Sep 21
    		$-9.00$-9.05+0.55%Beat+22.4%
    Jun 21
    		$-9.60$-9.35-2.67%Miss+38.5%
    Mar 21
    		$-9.20$-9.85+6.60%Beat-2.2%
    Dec 20
    		$-14.60$-12.85-13.62%Miss-14.1%
    Sep 20
    		$-11.60$-15.20+23.68%Beat+89.0%
    Jun 20
    		$-15.60$-12.05-29.46%Miss-4932.3%
    Mar 20
    		$-9.00$-11.35+20.70%Beat-
    Dec 19
    		$-12.80$-8.00-60.00%Miss-
    Sep 19
    		$-105.80$-78.87-34.14%Miss-
    Jun 19
    		$-0.31$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.74EV/EBITDA0.35x
    Price/FCF-3.52xFCF Yield-28.44%
    Profitability
    Profit Margin0.00%Operating Margin-255026.00%
    ROE-46.20%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio13.55xQuick Ratio13.55x
    Trading Statistics
    Beta1.59Avg Volume495.71K
    52-Week High$1.6952-Week Low$0.55

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.79
    SMA 20$0.72
    SMA 50$0.71
    SMA 200$0.83
    EMA 10$0.80
    EMA 20$0.75
    EMA 50$0.73
    EMA 200$0.92

    MACD

    Line: 0.05Signal: 0.03Hist: 0.02

    ADX

    ADX: 36.9+DI: 36.0-DI: 16.2

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down20.0
    PSAR$0.73

    Bollinger Bands

    Upper Band$0.94
    Lower Band$0.50
    %B Position6219%(Upper)
    Band Width0.68

    RSI (14-Day)

    Neutral
    56.0

    Momentum Oscillators

    Stoch %K39.1
    Stoch %D52.3
    Williams %R-67.0
    ROC (10d)15.9%
    Momentum0.11
    CCI (20d)62.1
    MFI (14d)79.6

    Volatility Measures

    ATR (14d)$0.09(11.3%)
    StdDev (20d)0.11
    Hist Vol125.7%(High)

    Volume Flow

    VWAP$0.81
    OBV122.0M
    AD Line-65.1M
    CMF (20d)-0.002

    Volume Metrics

    Avg Vol (20d)512.9K
    Vol Ratio0.9x
    VWMA (20d)$0.88

    Pivot Points

    R3$0.98
    R2$0.95
    R1$0.89
    Pivot Point$0.86
    S1$0.80
    S2$0.77
    S3$0.71

    Advanced Oscillators

    TSI22.98
    Ultimate Osc43.7
    KST157.95

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$3,337$1,848$118,111$162,463$205,817$354,621$561,574$380,569$14,075$319,468
    Cost of Revenue$0$0$-4,378,993$0$0$0$2.36M$0$0$0$2.05M$0
    Gross Profit$0$0$3,337$1,848$118,111$162,463$205,817$354,621$561,574$380,569$14,075$319,468
    Operating Expenses$4.03M$3.43M$2.65M$3.12M$3.51M$4.25M$3.43M$4.45M$4.41M$3.53M$3.69M$3.84M
    R&D$2.46M$1.61M$1.01M$1.64M$1.91M$2.48M$2.36M$2.85M$2.56M$1.60M$2.05M$2.12M
    SG&A$1.57M$1.82M$1.64M$1.48M$1.59M$1.76M$1.07M$1.61M$1.85M$1.93M$1.64M$1.72M
    Operating Income$-4,032,180$-3,430,412$-2,643,093$-3,117,388$-3,387,773$-4,085,582$-3,226,045$-4,097,016$-3,846,924$-3,149,670$-3,674,929$-3,522,850
    Interest Income$358,923$134,784$118,664$150,669$178,027$204,726$274,626$348,741$382,374$283,403$310,287$321,215
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-3,591,304$-3,287,917$-2,455,630$-2,972,410$-3,238,870$-3,932,659$-2,894,799$-3,783,769$-3,470,052$-2,810,091$-3,443,254$-3,204,515
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-3,591,304$-3,287,917$-2,455,630$-2,972,410$-3,238,870$-3,932,659$-2,894,799$-3,783,769$-3,470,052$-2,810,091$-3,443,254$-3,204,515
    EBITDA$-3,944,481$-3,417,273$-2,568,865$-3,117,650$-3,411,469$-4,131,956$-3,163,997$-4,127,081$-3,847,122$-3,087,337$-3,748,555$-3,524,298
    EBIT$-3,950,227$-3,422,701$-2,574,294$-3,123,079$-3,416,897$-4,137,385$-3,169,425$-4,132,510$-3,852,426$-3,093,494$-3,753,541$-3,525,730
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about APRE

    News

    Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5

    Maxim Group has reiterated its Buy rating for Aprea Therapeutics (APRE.US) and maintained its price target of $5. This indicates a continued positive outlook from the firm regarding the company's stock performance.

    Moomoo•8/15/26•
    Bullish

    Oppenheimer Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5

    Oppenheimer has reiterated its Buy rating for Aprea Therapeutics (APRE.US) and maintained its target price at $5. This indicates continued confidence from the firm in the company's prospects.

    Moomoo•8/14/26•
    Bullish

    Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com

    This article announces that Aprea Therapeutics Inc. filed a Form 8K on August 12, as reported by Investing.com. The brief entry reiterates the filing information and lists the company's stock symbol APRE.

    Investing.com Canada•8/13/26•
    Neutral

    Aprea Therapeutics Announces Second Quarter 2026 Financial Results

    Aprea Therapeutics (Nasdaq: APRE) reported its financial results for the second quarter ended June 30, 2026, highlighting $41.2 million in cash and cash equivalents. The company is accelerating enrollment in its Phase 1 ACESOT-1051 trial for oral WEE1 inhibitor APR-1051, with plans to advance it for uterine serous carcinoma and platinum-resistant ovarian cancer, and in combination regimens for HPV-positive head and neck cancer and colorectal cancer. Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity for APR-1051.

    The Manila Times•8/13/26•
    Somewhat-Bullish

    Aprea Therapeutics Releases Q2 2026 Financial Results

    Aprea Therapeutics, Inc. reported a narrower loss for Q2 2026, with a loss of $0.07 per share and a net loss of $3.6M, representing an 86.8% improvement from the prior year. The clinical-stage biopharmaceutical company is advancing its synthetic lethality-based cancer therapeutics pipeline, maintaining bullish analyst sentiment despite being in the development phase.

    AlphaStreet•8/12/26•
    Neutral

    Frequently Asked Questions About APRE

    Does APRE pay dividends?
    Aprea Therapeutics Inc (APRE) does not currently pay a regular dividend.
    What is APRE's market cap?
    Aprea Therapeutics Inc (APRE) has a market capitalization of $10.56M with a current stock price of $0.80.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In